A Non-Interventional Post-Authorisation Safety Study to Characterize Toxicity following Gemtuzumab Ozogamicin Treatment and Hematopoietic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia. | HMA-EMA Catalogues of real-world data sources and studies